Texas Emerges as Focus of New Trump Administration Actions to Limit Gender-Affirming Care - Scorecard - MDSpire

Texas Emerges as Focus of New Trump Administration Actions to Limit Gender-Affirming Care

  • By

  • Lindsey Dawson

  • May 21, 2026

  • 0 min

Share

Clinical Scorecard: Texas Becomes Central Point for Recent Trump Administration Efforts to Restrict Gender-Affirming Healthcare

At a Glance

CategoryDetail
ConditionGender-Affirming Care Restrictions
Key MechanismsFederal enforcement actions, subpoenas, and investigations targeting healthcare providers.
Target PopulationYouth seeking gender-affirming medical care.
Care SettingHealthcare institutions providing gender-affirming care.

Key Highlights

  • Texas has become a focal point for federal actions limiting gender-affirming care.
  • Over 40 healthcare institutions have reduced or ceased providing gender-affirming care since early 2025.
  • Federal subpoenas have been issued to multiple healthcare providers, including Rhode Island Hospital and NYU Langone Hospital.
  • Legal challenges are ongoing regarding the enforcement of subpoenas and the implications for patient privacy.
  • State Attorneys General are pushing back against federal actions to maintain access to care.

Guideline-Based Recommendations

Diagnosis

  • Monitor ongoing litigation and policy changes affecting gender-affirming care.

Management

  • Healthcare providers should remain informed about federal and state regulations regarding gender-affirming care.
  • Develop strategies for legal compliance and patient communication.

Monitoring & Follow-up

  • Continuously assess the impact of federal actions on the availability of gender-affirming care.

Risks

  • Potential legal repercussions for providers who do not comply with federal subpoenas.

Patient & Prescribing Data

Youth requiring gender-affirming medical interventions.

Providers are facing increased scrutiny and pressure regarding off-label prescribing practices.

Clinical Best Practices

  • Ensure compliance with state non-discrimination laws while navigating federal regulations.
  • Maintain clear communication with patients regarding potential changes in care availability.
  • Implement best practices for managing off-label prescribing under increased scrutiny.

Related Resources & Content

Original Source(s)

Related Content